

SEATTLE OVARIAN CANCER SPORE PUBLICATIONS LIST

October 1999 – October 2015

*An asterisk denotes each publication that is a result of formal collaborations among different projects within the SPORE, with other SPOREs, or with other funded NCI networks

Bold font has been used to highlight the names of POCRC investigators and DRP/CDP awardees with substantial effort on the FHCRC ovarian SPORE for all years.

Manuscripts that directly acknowledge the FHCRC SPORE in Ovarian Cancer, Pacific Ovarian Cancer Research, NIH P50 CA083636 Grant:

2015

Novak M, Lester J, Karst AM, Parkash V, Hirsch MS, Crum CP, **Karlan BY, Drapkin R**. Stathmin 1 and p16(INK4A) are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma. *Gynecol Oncol*. 2015 Oct;139(1):104-11. doi: 10.1016/j.ygyno.2015.07.100. Epub 2015 Jul 20. PMID: 26206555 PMCID: PMC4586950 [Available on 2016-10-01]

Elias KM, Emori MM, Papp E, MacDuffie E, Konecny GE, Velculescu VE, **Drapkin R**. Beyond genomics: Critical evaluation of cell line utility for ovarian cancer research. *Gynecol Oncol*. 2015 Oct;139(1):97-103. doi: 10.1016/j.ygyno.2015.08.017. Epub 2015 Aug 29. PMID: 26321251 PMCID: PMC4587360 [Available on 2016-10-01]

***Daly MB, Drescher CW**, Yates MS, Jeter JM, **Karlan BY**, Alberts DS, Lu KH. Salpingectomy as a means to reduce ovarian cancer risk. *Cancer Prev Res (Phila)*. 2015 May;8(5):342-8. doi: 10.1158/1940-6207.CAPR-14-0293. Epub 2015 Jan 13. Review. PMID: 25586903 [PubMed - in process] PMCID: PMC4417454 [Available on 2016-05-01] (P1)

Berguig GY, Convertine AJ, Frayo S, Kern HB, Procko E, Roy D, Srinivasan S, Margineantu DH, Booth G, **Palanca-Wessels MC**, Baker D, Hockenbery D, Press OW, Stayton PS. Intracellular delivery system for antibody-Peptide drug conjugates. *Mol Ther*. 2015 May;23(5):907-17. doi: 10.1038/mt.2015.22. Epub 2015 Feb 11. PMID: 25669432 [PubMed - in process] PMCID: PMC4427876 [Available on 2016-05-01] (CDP)

Liao JB, Ovenell KJ, Curtis EE, Cecil DL, Koehnlein MR, Rastetter LR, Gad EA, **Disis ML**. Preservation of tumor-host immune interactions with luciferase-tagged imaging in a murine model of ovarian cancer. *J Immunother Cancer*. 2015 May 19;3:16. doi: 10.1186/s40425-015-0060-6. eCollection 2015. PMID: 25992288 [PubMed] PMCID: PMC4437454 (P4)

Richter M, Yumul R, Wang H, Saydaminova K, Ho M, May D, Baldessari A, Gough M, **Drescher C, Urban N**, Roffler S, Zubieta C, Carter D, Fender P, **Lieber A**. Preclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicin. *Mol Ther Methods Clin Dev*. 2015 Mar 11;2:15005. doi: 10.1038/mtm.2015.5. eCollection 2015. PMID: 26029716 [PubMed] PMCID: PMC4445001 (P3)

Wu J, Yin H, Zhu J, Buckanovich RJ, Thorpe JD, Dai J, **Urban N**, Lubman DM. Validation of LRG1 as a potential biomarker for detection of epithelial ovarian cancer by a blinded study. *PLoS One*. 2015 Mar 23;10(3):e0121112. doi: 10.1371/journal.pone.0121112. eCollection 2015. PMID: 25799488 PMCID: PMC4370724 (P1)

Taylor-Harding B, Aspuria PJ, Agadjanian H, Cheon DJ, Mizuno T, Greenberg D, Allen JR, Spurka L, Funari V, Spiteri E, Wang Q, Orsulic S, Walsh C, **Karlan BY, Wiedemeyer WR**. Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS. *Oncotarget*. 2015 Jan 20;6(2):696-714. PMID: 25557169 [PubMed - in process] PMCID: PMC4359249 (P1)

Stephan SB, Taber AM, Jileaeva I, Pegues EP, Sentman CL, **Stephan MT**. Biopolymer implants enhance the efficacy of adoptive T-cell therapy. *Nat Biotechnol*. 2015 Jan;33(1):97-101. doi: 10.1038/nbt.3104. Epub 2014 Dec 15. PMID: 25503382 [PubMed - in process] PMCID: PMC4289408 (CDP)

2014

Andersen MR, Thorpe J, Buist DS, Beatty JD, Watabayashi K, Hanson N, Resta R, Chubak J, **Urban N**. Cancer Risk Awareness and Concern among Women with a Family History of Breast or Ovarian Cancer. *Behav Med*. 2014 Jul 25:1-11. [Epub ahead of print] PMID: 25062114 PMCID: PMC4469617 [Available on 2016-01-25] (P1)

Cai X, Dai Z, Reeves RS, Caballero-Benitez A, Duran KL, Delrow JJ, Porter PL, Spies T, **Groh V**. Autonomous stimulation of cancer cell plasticity by the human NKG2D lymphocyte receptor coexpressed with its ligands on cancer cells. *PLoS One*. 2014 Oct 7;9(10):e108942. doi: 10.1371/journal.pone.0108942. eCollection 2014. PMID: 25291178 [PubMed - indexed for MEDLINE] PMCID: PMC4188595 (DRP)

El-Gazzar A, Cai X, Reeves RS, Dai Z, Caballero-Benitez A, McDonald DL, Vazquez J, Gooley TA, Sale GE, Spies T, **Groh V**. Effects on tumor development and metastatic dissemination by the NKG2D lymphocyte receptor expressed on cancer cells. *Oncogene*. 2014 Oct 9;33(41):4932-40. doi: 10.1038/onc.2013.435. Epub 2013 Oct 21. PMID: 24141776 [PubMed - indexed for MEDLINE] PMCID: PMC3994187 (DRP)

Emori MM, **Drapkin R**. The hormonal composition of follicular fluid and its implications for ovarian cancer pathogenesis. *Reprod Biol Endocrinol*. 2014 Jul 6;12:60. doi: 10.1186/1477-7827-12-60. Review. PMID: 24997727 [PubMed - indexed for MEDLINE] PMCID: PMC4105128 (Core 1)

Cheon D-J, Tong Y, Cim M-S, Dering J, Berel D, Cui X, Lester J, Tighiouart M, Walts AE, **Karlan BY, Orsulic S**. A collagen-remodeling gene signature regulated by TGF β signaling is associated with metastasis and overall survival in serous ovarian cancer. *Clinical Cancer Research* 2014; 20:711–723. PMID:24218511 [PubMed - in process] PMCID:PMC3946428 (DRP)

***Karlan BY**, Thorpe J, Watabayashi K, **Drescher CW, Palomares M, Daly MB, Paley P, Hillard P, Andersen MR, Anderson G, Drapkin R, Urban N**. Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women. *Cancer Epidemiol Biomarkers Prev*. 2014 Jul;23(7):1383-93. doi: 10.1158/1055-9965.EPI-13-1361. Epub 2014 May 1. PMID: 24789859 [PubMed-in process] PMCID: PMC4082470 [Available on 2015-07-01] (P1)

Cheon DJ, **Orsulic S**. Ten-gene biomarker panel: a new hope for ovarian cancer? *Biomark Med*. 2014 Apr;8(4):523-6. doi: 10.2217/bmm.14.16. PMID: 24796616 [PubMed - in process] (DRP, Invited editorial)

*Topp MD, Hartley L, Cook M, Heong V, Boehm E, McShane L, Pyman J, McNally O, Ananda S, Harrell M, Etemadmoghadam D, Galletta L, Alsop K, Mitchell G, Fox SB, Kerr JB, Hutt KJ, Kaufmann SH, Australian Ovarian Cancer Study, **Swisher EM**, Bowtell DD, Wakefield MJ, Scott CL.: Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. *Molecular Oncology* 2014 8:656-668. PMID: 24560445 [PubMed - in process]. (P4)

Cecil DL, Holt GE, Park KH, Gad E, Rastetter L, Childs J, Higgins D, **Disis ML**. Elimination of IL-10-Inducing T-Helper Epitopes from an IGF2BP-2 Vaccine Ensures Potent Antitumor Activity. *Cancer Res*. 2014 Apr 28. [Epub ahead of print]. DOI: 10.1158/0008-5472.CAN-13-3286. PMID: 24778415. (P5)

Palanca-Wessels MC, Press OW. Advances in the treatment of hematologic malignancies using immunoconjugates. *Blood*. 2014 Apr 10;123(15):2293-301. doi: 10.1182/blood-2013-10-492223. Epub 2014 Feb 27. PMID: 24578502 PMCID: PMC3983610. [Available on 2015/4/10] (CDP)

Wiedemeyer WR, Beach JA, **Karlan BY**. Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System. *Front Oncol*. 2014 Mar 3;4:34. eCollection 2014. PMID: 24624361; PMCID: PMC3939430. (CDP)

Miller CP, Thorpe JD, Kortum AN, Coy CM, Cheng WY, Ou Yang TH, Anastassiou D, **Beatty JD, Urban ND, Blau CA**. JAK2 expression is associated with tumor-infiltrating lymphocytes and improved breast cancer outcomes: implications for evaluating JAK2 inhibitors. *Cancer Immunol Res*. 2014 Apr;2(4):301-6. doi: 10.1158/2326-6066.CIR-13-0189. Epub 2014 Jan 15. PMID: 24764577 [PubMed - in process] (Core A - Avon Supplement)

Cermelli S, Jang I, Bernard B, and **Grandori C**. Synthetic lethal screens as a means to understand and treat MYC-driven cancers. *Cold Spring Harb Perspect Med*. 2014 Mar 1;4(3). pii: a014209. doi: 10.1101/cshperspect.a014209. PMID:24591535[PubMed - in process]. (DRP)

*Conner JR, Meserve E, **Pizer E**, Garber J, Roh M, **Urban N, Drescher C**, Quade BJ, Muto M, Howitt BE, Pearlman MD, Berkowitz RS, Horowitz N, Crum CP, Feltmate C. Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations. *Gynecol Oncol*. 2014 Feb;132(2):280-6. doi: 10.1016/j.ygyno.2013.12.009. Epub 2013 Dec 12. PMID: 24333842 [PubMed - in process] (Core C)

Lutz AM, Bachawal SV, **Drescher CW**, Pysz MA, **Willmann JK, Gambhir S**. Ultrasound Molecular Imaging in a Human CD276 Expression-Modulated Murine Ovarian Cancer Model. *Clin Cancer Res*. 2014 Mar 1;20(5):1313-22. doi: 10.1158/1078-0432.CCR-13-1642. Epub 2014 Jan 3. PMID:24389327[PubMed - in process]. (P2)

2013

Disis ML, Gad E, Herendeen DR, Lai VP, Park KH, Cecil DL, O'Meara MM, Treuting PM, Lubet RA. A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease. *Cancer Prev Res (Phila)*. 2013 Dec;6(12):1273-82. doi: 10.1158/1940-6207.CAPR-13-0182. Epub 2013 Oct 23. PMID:24154719 [PubMed - in process]. (P5)

Robins HS, Ericson N, Guenthoer J, O'Briant KC, **Tewari M, Drescher CW**, Bielas JH. Digital quantification of tumor infiltrating lymphocytes. *Sci Transl Med*, 2013 Dec 4;5(214):214ra169. doi: 10.1126/scitranslmed.3007247. PMID:24307693. (Core B, Core C)

Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, Thornton A, Norquist BM, Casadei S, Nord AS, Agnew KJ, Pritchard CC, Scroggins S, Garcia RL, King M, **Swisher EM**. Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. *Clin Cancer Res*. 2014 Feb 1;20(3):764-75. doi: 10.1158/1078-0432.CCR-13-2287. Epub 2013 Nov 15. PMID: 24240112 [PubMed - indexed for MEDLINE] PMCID: PMC3944197 (P4)

Cheon DJ, Tong Y, Sim MS, Dering J, Berel D, Cui X, Beach JA, Lester J, Tighiouart M, Walts A, **Karlan BY, Orsulic S**. A collagen-remodeling gene signature regulated by TGF- β signaling is associated with metastasis and poor survival in serous ovarian cancer. *Clin Cancer Res*. 2013 Nov 11. [Epub ahead of print]. PMCID:PMC3946428. (Core B)

El-Gazzar A, Cai X, Reeves RS, Dai Z, Caballero-Benitez A, McDonald DL, Vazquez J, Gooley TA, Sale GE, Spies T, **Groh V**. Effects on tumor development and metastatic dissemination by the NKG2D lymphocyte receptor expressed on cancer cells. *Oncogene*. 2013 Oct 21. doi: 10.1038/onc.2013.435. [Epub ahead of print]. PMID:24141776. (DRP)

Strauss R, Bartek J, **Lieber A**. Analysis of EMT by flow cytometry and immunohistochemistry. *Methods Mol Biol*. 2013;1049:355-68. doi: 10.1007/978-1-62703-547-7_27. PMID: 23913230. (P3b)

Pennington KP, Wickramanayake A, Norquist BM, Pennil CC, Garcia RL, Agnew KJ, **Taniguchi T, Welcsh P, Swisher EM**. 53BP1 expression in sporadic and inherited ovarian carcinoma: Relationship to genetic status and clinical outcomes. *Gynecol Oncol*. 2013 128(3):493-9. PMCID: PMC3889639 (P4).

Hindson CM, Chevillet JR, Briggs HA, Gallichotte EN, Ruf IK, Hindson BJ, Vessella RL, and **Tewari M**. Absolute quantification by droplet digital PCR versus analog real-time PCR. *Nat Methods*. 2013 Oct;10(10):1003-5. doi: 10.1038/nmeth.2633. Epub 2013 Sep 1. PMID:23995387. (P3a)

Johnson N, Johnson SF, Yao W, Li YC, Choi YE, Bernhardt AJ, Wang Y, Capelletti M, Sarosiek KA, Moreau LA, Chowdhury D, Wickramanayake A, Harrell MI, Liu JF, D'Andrea AD, Miron A, **Swisher EM**, Shapiro GI. Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. *Proc Natl Acad Sci U S*

A. 2013 Oct 15;110(42):17041-6. doi: 10.1073/pnas.1305170110. Epub 2013 Oct 1. PMID:PMC3801063. (P4)

Emerson RO, Sherwood AM, Rieder MJ, Guenthoer J, Williamson DW, Carlson CS, **Drescher CW, Tewari M**, Bielas JH, Robins HS. High-throughput sequencing of T cell receptors reveals a homogeneous repertoire of tumor-infiltrating lymphocytes in ovarian cancer. *J Pathol*. 2013 Sep 11. doi: 10.1002/path.4260. [Epub ahead of print]. PMID:24027095. [PubMed in process]. (Core B, Core C)

Wang H, Yumul R, Cao H, Ran L, Fan X, Richter M, Epstein F, Gralow J, Zubieta C, Fender P, **Lieber A**. Structural and functional studies on the interaction of adenovirus fiber knob domains and desmoglein 2. *J Virol*. 2013. Nov;87(21):11346-62. doi: 10.1128/JVI.01825-13. Epub 2013 Aug 14. PMID:PMC3807342. (P3b)

Norquist BM, Pennington KP, Agnew KJ, Harrell MI, Pennil CC, Lee MK, Casadei S, Thornton AM, Garcia RL, Walsh T, Swisher EM. Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testing. *Gynecol Oncol*. 2013 128(3):483-7. PMID:PMC3913382 (P4)

Drescher CW, Shah C, Thorpe J, O'Briant K, **Anderson GL**, Berg CD, **Urban N, McIntosh MW**. A Longitudinal Screening Algorithm that Incorporates Change Over Time in CA125 Levels Identifies Ovarian Cancer Earlier than a Single Threshold Rule. *J Clin Oncol*. 2013 Jan 20;31(3):387-92. doi: 10.1200/JCO.2012.43.6691. PMID: PMC3732015 (Core C)

Liao JB, Disis ML. Therapeutic vaccines for ovarian cancer. *Gynecol Oncol*. 2013 Sep;130(3):667-73. doi: 10.1016/j.ygyno.2013.06.023. Epub 2013 Jun 22. PMID:23800697 Review. PMID: Not needed (P5)

Hellström I, Swisher E, Hellström KE, Yip YY, Agnew K, **Luborsky JL**. Anti-HE4 antibodies in infertile women and women with ovarian cancer. *Gynecol Oncol*. 2013. pii: S0090-8258(13)00761-0. doi: 10.1016/j.ygyno.2013.05.028. [Epub ahead of print]. PMID: PMC3748160 (DRP)

2012

Beyer I, Cao H, Persson J, Song H, Richter M, Feng Q, Yumul R, van Rensburg R, Li ZY, Berenson R, Carter D, Roffler S, **Drescher C, Lieber A**. Co-administration of epithelial junction opener JO-1 improves the efficacy and safety of chemotherapeutic drugs. *Clin Cancer Res*. 2012 Jun 15;18(12):3340-51. PMID: PMC3547677 (P3b)

Drescher CW, Hawley S, Thorpe JD, Marticke S, **McIntosh MW, Gambhir SS, Urban N**. Impact of screening test performance and cost on mortality reduction and cost-effectiveness of multimodal ovarian cancer screening. *Cancer Prev Res (Phila)*. 2012 Aug;5(8):1015-24. PMID: PMC3729263. (P2)

Barua A, Yellapa A, Bahr JM, Abramowicz JS, Edassery SL, Basu S, Rotmensch J and Bitterman P. Expression of death receptor 6 (DR6) by ovarian tumors in laying hens, a preclinical model of spontaneous ovarian cancer. *Translational Oncology*, 2012; 5 (4), 260-268. PMID: PMC3431036. (CDP)

Swisher E, Walsh T: BRCA1 and BRCA2 mutations in ovarian cancer. *JAMA* 307:359-360; author reply 360-351, 2012. PMID: 22274679. (P4)

Knouf E, Garg K, Arroyo J, Correa Y, Sarkar D, Parkin R, Wurz K, O'Briant K, Godwin A, **Urban N**, Ruzzo W, **Gentleman R, Drescher C, Swisher E, Tewari M**. An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcription. *Nucleic Acids Res*. 2012 Jan 1;40(2):499-510. PMID: PMC3258134. (P3a)

Pritchard CC, Cheng HH, **Tewari M**. MicroRNA profiling: approaches and considerations. *Nature reviews Genetics*. 2012 May;13(5):358-69. Invited Review (*Not peer-reviewed, no PMID required*). (P3a)

Schummer M, **Drescher C**, Forrest R, Gough S, Thorpe J, **Hellström I, Hellström KE, Urban N**. Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125. *Gynecol Onc*. 2012 Apr;125(1):65-9. PMID: PMC3303992 (Core B)

Sun Y, Campisi J, Higano C, Beer TH, Porter P, Coleman, True L, Nelson PS. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. 2012 Sep;18(9):1359-68. doi: 10.1038/nm.2890. PMID: PMC3677971. (Core B)

Swisher EM, Taniguchi T, Karlan BY. Molecular scores to predict ovarian cancer outcomes: a worthy goal, but not ready for prime time. *J Natl Cancer Inst*. 2012 May 2;104(9):642-5. PMID: PMC3341312 (P4)

***Urban N**, Thorpe J, **Karlan BY**, **McIntosh MW**, **Palomares MR**, **Daly MB**, **Paley P**, **Drescher CW**. Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer. *Cancer Epidemiol Biomarkers Prev*. 2012 Nov;21(11):2087-94. PMID: PMC3493821. (P1)

Wender PA, Galliher WC, Bhat NM, Pillow TH, Bieber MM, **Teng NN**. Taxol-oligoarginine conjugates overcome drug resistance in-vitro in human ovarian carcinoma. *Gynecol Oncol*. 2012 Jul;126(1):118-23. PMID: PMC3883629. (Cites POCRC but doesn't provide grant #) (DRP)

Wickramanyake A, Bernier G, Pennil C, Casadei S, Agnew KJ, Stray SM, Mandell J, Garcia RL, Walsh T, King MC, **Swisher EM**. Loss of function germline mutations in RAD51D in women with ovarian carcinoma. *Gynecol Oncol*. 2012 Dec;127(3):552-5. PMID: PMC3905744. (P4)

Pritchard CC1, Kroh E, Wood B, Arroyo JD, Dougherty KJ, Miyaji MM, Tait JF, **Tewari M**. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. *Cancer Prev Res (Phila)*. 2012 Mar;5(3):492-7. doi: 10.1158/1940-6207.CAPR-11-0370. Epub 2011 Dec 12. NIHMS344003. (P3a)

2011

Barua A, Bitterman P, Bahr JM, Basu S, Sheiner E, Bradaric MJ, Hales DB, **Luborsky JL**, Abramowicz JS. Contrast-enhanced Ultrasound Detects Spontaneous Ovarian Cancer at Early Stage in a Preclinical Animal Model. 2011 Mar;30(3):333-45. PMID: PMC3105598 (CDP)

Beyer I, Li Z, Persson J, Liu Y, van Rensburg R, Yumul R, Zhang XB, Hung MC, **Lieber A**. Controlled extracellular matrix degradation in breast cancer tumors improves therapy by trastuzumab. *Mol Ther*. 2011 Mar;19(3):479-89. PMID: PMC3048180. (DRP)

Beyer I, van Rensburg R, Strauss R, Li Z, Wang H, Persson J, Yumul R, Feng Q, Song H, Bartek J, Fender P, **Lieber A**. Epithelial Junction Opener JO-1 Improves Monoclonal Antibody Therapy of Cancer. *Cancer Res*. 2011 Nov 15;71(22):7080-90. PMID: PMC3217128. (DRP)

*Cramer DW, Bast RC, Berg CD, Diamandis EP, **Godwin AK**, Hartge P, Lokshin AE, Lu KH, McIntosh MW, Mor G, Patriotic C, Pinsky PF, Thornquist MD, **Scholler N**, Skates SJ, Sluss PM, Srivastava S, Ward DC, Zhang Z, Zhu CS, **Urban N**. Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Specimens. *Cancer Prev Res (Phila)*. 2011 Mar;4(3):365-74. PMID: PMC3085251. (P1)

Dhillon KK, **Swisher EM**, **Taniguchi T**. Secondary mutations of BRCA1/2 and drug resistance. *Cancer Sci*. 2011 Apr;102(4):663-9. doi: 10.1111/j.1349-7006.2010.01840.x. PMID: PMC3095365 (P4)

Liu Y, **Tuve S**, Persson J, Beyer I, Yumul R, Li Z, Tragoolpua K, **Hellström KE**, Roffler S, **Lieber A**. Adenovirus-mediated intratumoral expression of immunostimulatory proteins in combination with systemic Treg inactivation induces tumor-destructive immune responses in mouse models. *Cancer Gene Therapy*. 2011 Jun;18(6):407-18. PMID: PMC3096725. (CDP)

Luborsky JL, Yu Y, Edassery SL, Jaffar J, Yip YY, Liu P, **Hellström KE**, **Hellström I**. Autoantibodies to Mesothelin in Infertility. *Cancer Epidemiol Biomarkers Prev*. 2011 Sep;20(9):1970-8. PMID: PMC3304582. (DRP)

Miller CP, **Urban N**, Blau CA. Quantitative Comparison of Erythropoietin Receptor Levels in the Epithelial versus Endothelial Fractions of Primary Breast Tumors. *Anticancer Res*. 2011 Apr;31(4):1189-95. PMID: PMC3401416. (Core A)

Norquist B, Wurz K, Pennil CC, Garcia R, Gross J, Sakai W, **Karlan B**, **Taniguchi T**, **Swisher EM**. Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas. *J Clin Oncol*. 2011 Aug 1;29(22):3008-15. PMID: PMC3157963. (P4)

Salzman J, Marinelli RJ, Wang PL, Green AE, Nielsen JS, Nelson BH, **Drescher CW**, Brown PO. ESRRA-C11orf20 Is a Recurrent Gene Fusion in Serous Ovarian Carcinoma. *PLoS Biology*. 2011 Sep;9(9):e1001156. PMID: PMC3176749. (P2)

Strauss R, Li Z, Liu Y, Beyer I, Persson J, **Sova P**, Moller T, Pesonen S, Hemminki A, Hamerlik P, **Drescher CW**, **Urban N**, Bartek J, **Lieber A**. Analysis of Epithelial and Mesenchymal Markers in Ovarian Cancer Reveals Phenotypic Heterogeneity and Plasticity. *PLoS ONE*. 2011 Jan 14;6(1):e16186. PMID: PMC3021543. (CDP)

Wang H, Li Z, Yumul R, Lara S, Hemminki A, Fender P, **Lieber A**. Multimerization of adenovirus serotype 3 fiber knob domains is required for efficient binding of virus to desmoglein 2 and subsequent opening of epithelial junctions. *Journal of Virology*, 2011 85(13):6390-402. PMID: PMC3112237 (DRP)

Urban N. Designing early detection programs for ovarian cancer. *Annals of Oncology* 2011 Dec;22 (Supplement 8): viii16–viii18. doi:10.1093/annonc/mdr472. PMID: PMC3280618. (P1)

Urban N, Thorpe JD, Bergan LA, Forrest RM, Kampani AV, **Scholler N**, O'Briant KC, **Anderson GL**, Cramer DW, Berg CD, **McIntosh MW**, Hartge P, **Drescher CW**. Potential role of HE4 in multimodal screening for epithelial ovarian cancer. *J Natl Cancer Inst*. 2011 Nov 2;103(21):1630-4. PMID: PMC3206037. (P1)

Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, Roeb W, Agnew KJ, Stray SM, Wickramanayake A, Norquist B, Pennington KP, Garcia RL, King MC, **Swisher EM**. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. *Proc Natl Acad Sci U S A*. 2011 Nov 1;108(44):18032-7. PMID: PMC3207658. (P4)

Wang H, Li ZY, Liu Y, Persson J, Beyer I, Möller T, Koyuncu D, Drescher MR, Strauss R, Zhang XB, Wahl JK, **Urban N**, **Drescher C**, Hemminki A, Fender P, **Lieber A**. Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11, and 14. *Nature Medicine*. 2011 Jan; 17(1):96-104. PMID: PMC3074512. (DRP)

Yu Y, Edassery SL, **Barua A**, Abramowicz JS, Bahr JM, **Hellström I**, **Luborsky JL**. The hen model of human ovarian cancer develops anti-mesothelin autoantibodies in response to mesothelin expressing tumors. *J Ovarian Res*. 2011 Jul 29;4(1):12. PMID: PMC3163210. (CDP)

Zhao A, Nuñez-Cruz S, Li C, Coukos G, Siegel DL, **Scholler N**. Rapid isolation of high-affinity human antibodies against the tumor vascular marker Endosialin/TEM1, using a paired yeast-display/secretory scFv library platform. *J Immunol Methods*. 2011 Jan 5;363(2):221-32. PMID: PMC3003766. (DRP)

*Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, **Urban N**, Mor G, Bast RC, Moore LE, Lokshin AE, **McIntosh MW**, Skates SJ, Vitonis A, Zhang Z, Ward DC, Symanowski JT, Lomakin A, Fung ET, Sluss PM, **Scholler N**, Lu KH, Marrangoni AM, Patriotis C, Srivastava S, Buys SS, Berg CD. For the PLCO Project Team. A Framework for Evaluating Biomarkers for Early Detection: Validation of Biomarker Panels for Ovarian Cancer. *Cancer Prev Res (Phila)*. 2011 Mar;4(3):375-83. PMID: PMC3057372. (P1)

2010

Abdul-Alim CS, Li Y, **Yee C**. Conditional Superagonist CTL Ligands for the Promotion of Tumor-Specific CTL Responses. *J Immunol*. 2010 Jun 1;184(11):6514-21. PMID: PMC3313650. (DRP)

Amon L, Law W, Fitzgibbon M, Gross J, O'Briant K, Peterson A, **Drescher C**, Martin D, **McIntosh M**. Integrative Proteomic Analysis of Serum and Peritoneal Fluids Helps Identify Proteins that Are Up-Regulated in Serum of Women with Ovarian Cancer. *PLoS ONE*. 2010 Jun;5(6):e111137. PMID: PMC2886122. (Core D)

Andersen MR, **Goff BA**, **Lowe KA**, **Scholler N**, Bergan L, **Drescher CW**, **Paley P**, **Urban N**. Use of a Symptom Index, CA125 and HE4 to predict ovarian cancer. *Gyn Onc*. 2010 Mar; 116(3):378-383. PMID: PMC2822097. (Core A?)

Anderson GL. Ovarian cancer biomarker screening: still too early to tell. *Womens Health (Lond Engl)*. 2010 Jul;6(4):487-90. Review. (*Not peer-reviewed, no PMID required*). (Core A)

***Anderson GL**, **McIntosh MW**, Wu L, Barnett M, Goodman G, Thorpe JD, Bergan L, Thornquist MD, **Scholler N**, Kim N, O'Briant K, **Drescher C**, **Urban N**. Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case–Control Study. *J Natl Cancer Inst*. 2010 Jan 6;102(1):26–38. PMID: PMC2802285. (P1)

Barua A, Bitterman P, Bahr JM, Bradaric MJ, Hales DB, **Luborsky JL**, Abramowicz JS. Detection of tumor-associated neoangiogenesis by Doppler ultrasonography during early-stage ovarian cancer in laying hens: a preclinical model of human spontaneous ovarian cancer. *J Ultrasound Med*. 2010 Feb;29(2):173-82. PMID: PMC3105600. (CDP)

Bendoraitė A, Knouf EC, Garg KS, Parkin RK, Kroh EM, O'Briant KC, Ventura AP, **Godwin AK**, **Karlan BY**, **Drescher CW**, **Urban N**, **Knudsen B**, **Tewari M**. Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: Evidence supporting a mesothelial-to-epithelial transition. *Gyn Onc*. 2010 Jan;116(1):117-25. PMID: PMC2867670. (P3a)

Eddy JA, **Hood L, Price ND**, Geman D. Identifying tightly regulated and variably expressed pathways by Differential Rank Conservation (DIRAC). *PLoS Computational Biology*. 2010 May 27;6(5):e10000792. PMID: PMC2877722. (DRP)

Eddy JA, Sung J, Geman D, **Price ND**. Relative Expression Analysis for Molecular Cancer Diagnosis and Prognosis. *Technol Cancer Res Treat*. 2010 Apr;9(2):149-59. PMID: PMC2921829. (DRP)

Houshdaran S, Hawley S, Palmer C, Campan M, Olsen MN, Ventura AP, **Knudsen BS, Drescher CW, Urban ND**, Brown PO, Laird PW. DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines. *PLoS ONE*. 2010 Feb 22;5(2):e9359. PMID: PMC2825254. (Core B)

Kroh EM, Parkin RK, Mitchell PS, **Tewari M**. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). *Methods*. 2010 Apr;50(4):298-301. NIH MID: NIHMS177877. (P3a)

Ramirez AB, Loch CM, Zhang Y, Liu Y, Wang X, Wayner EA, Sargent JE, Sibani S, Hainsworth E, Mendoza EA, Eugene R, LaBaer J, **Urban N, McIntosh MW**, Lampe PD. Use of a single chain antibody library for ovarian cancer biomarker discovery. *Mol Cell Proteomics*. 2010 Jul;9(7):1449-60. PMID: PMC2938096. (Core B)

Schummer M, Beatty D, **Urban N**. Breast Cancer Genomics: Normal Tissue and Cancer Markers. *Ann N Y Acad Sci*. 2010 Oct;1210:78-85. PMID: 20973801. (Core B)

[Schummer M, Green A, Beatty JD, Karlan BY, Karlan S, Gross J, Thornton S, McIntosh M, Urban N.](#) Comparison of breast cancer to healthy control tissue discovers novel markers with potential for prognosis and early detection. *PLoS One*. 2010 Feb 9;5(2):e9122. doi: 10.1371/journal.pone.0009122. PMID: PMC2817747. (Core B)

Ventura AP, Radhakrishnan S, Green A, Rajaram SK, Allen AN, O'Briant KO, **Schummer M, Karlan B, Urban N, Tewari M, Drescher C, Knudsen BS**. Activation of the MEK-S6 Pathway in High-grade Ovarian Cancers. [Appl Immunohistochem Mol Morphol](#). 2010 Dec;18(6):499-508. PMID: PMC2989426. (DRP)

Wilson BK, Mentele T, Bachar S, Knouf E, Bendoraite A, **Tewari M**, Pun SH, Lin LY. Nanostructure-enhanced laser tweezers for efficient trapping and alignment of particles. *Optics express*. 2010 Jul 19;18(15):16005-13. PMID: PMC3387742. (P3a)

*Wurz K, Garcia RL, Goff BA, Mitchell PS, Lee JH, **Tewari M, Swisher EM**. miR-221 and miR-222 alterations in sporadic ovarian carcinoma: Relationship to CDKN1B, CDKN1C and overall survival. *Genes Chromosomes Cancer*. 2010 Jul;49(7):577-84. PMID: PMC2869465. (P3a)

2009

Edelman LB, Toia G, Geman D, Zhang W, **Price ND**. Two-transcript gene expression classifiers in the diagnosis and prognosis of human diseases. *BMC Genomics*. 2009 Dec 5;10:583. PMID: PMC2797819. (DRP)

Chen A, Kozak D, Battersby B, Forrest R, **Scholler N, Urban N**, Trau M. Antifouling Surface Layers for Improved Signal-to-Noise of Particle-Based Immunoassays. *Langmuir*. 2009 Dec 1;25(23):13510-5. PMID: PMC2891774. (Core B)

Barua A, Bitterman P, Abramowicz JS, Dirks AL, Bahr JM, Hales DB, Bradaric MJ, Edassery SL, Rotmensch J, **Luborsky JL**. Histopathology of ovarian tumors in laying hens: a preclinical model of human ovarian cancer. *Int J Gynecol Cancer*. 2009 May;19(4):531-9. PMID: PMC2759668. (CDP)

Eddy JA, **Price ND**, Geman D. Relative expression analysis for identifying perturbed pathways. *IEEE Eng Med Bio Soc*. 2009:5456-9. PMID: PMC2923586. (DRP)

Li Z, Liu Y, **Tuve S**, Xun Y, Fan X, Min L, Feng Q, **Kiviat N**, Kiem HP, **Disis ML, Lieber A**. Towards a stem cell gene therapy for breast cancer. *Blood*. 2009 May 28;113(22):5423-33. PMID: PMC2689044. (CDP)

Lowe KA, Andersen MR, Urban N, Paley P, Drescher CW, Goff BA. The temporal stability of the Symptom Index among women at high-risk for ovarian cancer. *Gynecol Oncol*. 2009 Aug;114(2):225-30. PMID: PMC2736546. (Core D)

McTiernan A, Wang CY, Sorensen B, Xiao L, Buist DS, Aiello Bowles EJ, **White E, Rossing MA, Potter J, Urban N**. No effect of aspirin on mammographic density in a randomized controlled clinical trial. *Cancer Epidemiol Biomarkers Prev*. 2009 May;18(5):1524-30. PMID: PMC2689709. (Core A)

Pan S, Cheng L, White JT, Lu W, Utleig AG, Yan X, **Urban ND, Drescher CW, Hood L, Lin B**. Quantitative Proteomic Analysis Integrated with Microarray Data Reveals That Extracellular Matrix Proteins, Catenins, and P53 Binding Protein 1 Are Important for Chemotherapy Response in Ovarian Cancers. *OMICS*. 2009 Aug;13(4):345-54. NIHMIID: NIHMS233671. (Core A?)

Pitteri SJ, JeBailey L, Faça VM, Thorpe JD, Silva MA, Ireton RC, Horton MB, Wang H, Pruitt LC, Zhang Q, Cheng KH, **Urban N**, Hanash SM, Dinulescu DM. Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery. *PLoS ONE*. 2009;4(11):e7916. PMID: PMC2775948 (Core D)

Strauss R, **Sova P**, Liu Y, Li Z, **Tuve S**, Pritchard D, Brinkkoetter P, Moller T, Wildner O, Pesonen S, Hemminki A, **Urban N, Drescher CW, Lieber A**. Epithelial Phenotype Confers Resistance of Ovarian Cancer Cells to Oncolytic Adenoviruses. *Cancer Res*. 2009 Jun 15;69(12):5115-25. PMID: PMC2738419

Shah CA, **Lowe KA, Paley P**, Wallace E, **Anderson GL, McIntosh MW, Andersen MR, Scholler N**, Bergan LA, Thorpe JD, **Urban N, Drescher CW**. Influence of Ovarian Cancer Risk Status on the Diagnostic Performance of the Serum Biomarkers Mesothelin, HE4, and CA125. *Cancer Epidemiol Biomarkers Prev*. 2009 May;18(5):1365-72. PMID: PMC2714056

Tuve S, Liu Y, Tragoolpua K, Jacobs JD, Yumul RC, Li ZY, Strauss R, Hellström KE, **Disis ML**, Roffler S, **Lieber A**. In situ adenovirus vaccination engages T effector cells against cancer. *Vaccine*. 2009 Jun 24;27(31):4225-39. PMID: PMC2727281

Schilder RJ, Pathak HB, Lokshin AE, Holloway RW, Alvarez RD, Aghajanian C, Min H, Devarajan K, Ross E, **Drescher CW, Godwin AK**. Phase II trial of single agent Cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. *Gynecol Oncol*. 2009 Apr;113(1):21-7. PMID: PMC2741166

Wyman SK, Parkin RK, Mitchell PS, Fritz BR, O'Briant K, **Godwin AK, Urban N, Drescher CW, Knudsen BS, Tewari M**. Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. *PLoS ONE*. 2009;4(4):e5311. PMID: PMC2668797

Sarkar D, Parkin R, Wyman S, Bendoraite A, Sather C, Delrow J, **Godwin AK, Drescher C**, Huber W, **Gentleman R, Tewari M**. Quality Assessment and Data Analysis for microRNA Expression Arrays. *Nucleic Acids Res*. 2009 Feb;37(2):e17. PMID: PMC2632898

Knudsen BS, Zhao P, Resau J, Cottingham S, Gherardi S, Xu E, Berghuis B, Daugherty J, Grabinski T, Toro J, Giambernardi T, Skinner RS, Gross M, Hudson E, Kort E, Lengyel E, Ventura A, Xie Q, Hay R, Vande Woude G, Cao B. A novel multipurpose monoclonal antibody for evaluating human c-MET expression in preclinical and clinical settings. *Appl Immunohistochem Mol Morphol*. 2009 Jan;17(1):57-67. PMID: PMC2952101. (DRP)

2008

Andersen MR, Goff B, Lowe K, Scholler N, Bergan L, **Urban N**. Combining a symptoms index with CA125 to improve detection of ovarian cancer. *Cancer*. 2008 Aug 1;113(3):484-9. PMID: PMC2734274

Feng, Q, Deftereos G, Hawes S, Stern J, Willner JB, **Swisher E**, Xi L, **Drescher CW, Urban N, Kiviat N**. DNA Hypermethylation, Her-2/neu Overexpression and p53 Mutations in Ovarian Carcinoma Corresponding. *Gynecol Oncol*. 2008 Nov;111(2):320-9. PMID: PMC2642648

Knudsen BS, Vande Woude G. Showering c-MET-dependent cancers with drugs. *Curr Opin Genet Dev*. 2008 Feb;18(1):87-96. Not eligible for NIH Public Access Policy.

Li Y, **Yee C**. IL-21 mediated FoxP3 suppression leads to enhanced generation of antigen-specific CD8+ CTL. [Blood](#). 2008 Jan 1;111(1):229-35. PMID: PMC2200808

Lowe K, Shah C, Wallace E, **Anderson G**, **Paley P**, **McIntosh M**, **Andersen M**, **Scholler N**, Bergan L, Thorpe J, **Urban N**, **Drescher C**. Effects of Personal Characteristics on Serum CA125, Mesothelin, and HE4 Levels in Healthy Post-menopausal Women at High-Risk for Ovarian Cancer. *Cancer Epidemiol Biomarkers Prev*. 2008 Sep;17(9):2480-7. PMID: PMC2632599

Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J., O'Briant KC, Allen A, Lin DW, **Urban N**, **Drescher CW**, **Knudsen BS**, Stirewalt DL, **Gentleman R**, Vessella RL, Nelson PS, Martin DB, **Tewari M**. Circulating microRNAs as stable blood-based markers for cancer detection. *Proc Natl Acad Sci U S A*. 2008 Jul 29;105(30):10513-8. PMID: PMC2492472

Nelson BH. The impact of T-cell immunity on ovarian cancer outcomes. *Immunol Rev*. 2008 Apr;222:101-16. Review. Not eligible for NIH Public Access Policy.

Oron A, Jiang Z, **Gentleman R**. Gene Set Enrichment Analysis Using Linear Models and Diagnostics. *Bioinformatics*. 2008 Nov 15;24(22):2586-91. PMID: PMC2579710

Palmer C, Duan X, Hawley S, **Scholler N**, Thorpe JD, Sahota RA, Wong MQ, Wray A, Bergan L, **Drescher CW**, **McIntosh M**, Brown P, **Nelson B**, **Urban N**. Systematic evaluation of candidate blood markers for detecting ovarian cancer. *PLOS ONE*. 2008 Jul 9;3(7):e2633. PMID: PMC2440813

Price ND, Foltz G, Madan A, **Hood L**, Tian Q. Systems biology and cancer stem cells. *J Cell Mol Med*. 2008 Jan-Feb;12(1):97-110. Not eligible for NIH Public Access Policy.

Sakai W, **Swisher EM**, **Karlan BY**, Agarwal MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Farrugia DJ, Couch FJ, **Urban N**, **Taniguchi T**. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. *Nature*. 2008 Feb 28;451(7182):1116-20. PMID: PMC2577037

Scholler N, Gross J, Garvik BM, Wells L, Liu Y, Loch C, Ramirez A, **McIntosh MW**, Lampe P, **Urban N**. Use of cancer-specific yeast-secreted in vivo biotinylated recombinant antibodies for serum biomarker discovery. *Journal of Translational Medicine*. 2008 Jul 24;6(1):41. PMID: PMC2503970

Scholler N, **Lowe KA**, Bergan LA, Kampani AV, Ng V, Forrest RM, Thorpe JD, Gross JA, Garvik BM, Drapkin R, **Anderson GL**, **Urban N**. Use of yeast-secreted in vivo biotinylated recombinant antibodies (biobodies) in bead-based ELISA. *Clinical Cancer Research*. 2008 May 1;14(9):2647-55. PMID: PMC2744596

Swisher EM, Sakai W, **Karlan BY**, Wurz K, **Urban N**, **Taniguchi T**. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. *Cancer Res*. 2008 Apr 15;68(8):2581-6. PMID: PMC2674369

Urban N, **Drescher C**. Potential and limitations in early diagnosis of ovarian cancer. *Advances in Experimental Medicine and Biology*. 2008 ;622:3-14. Review. Not eligible for NIH Public Access Policy.

Walsh CS, Ogawa S, Karahashi H, **Scoles DR**, Pavelka JC, Tran H, Miller CW, Kawamata N, Ginther C, Dering J, Sanada M, Nannya Y, Slamon DJ, Koeffler PH, **Karlan BY**. ERCC5 is a novel biomarker of ovarian cancer prognosis. *J Clin Oncol*. 2008 Jun 20;26(18):2952-8. Not eligible for NIH Public Access Policy. Accepted for publication March 4, 2008.

2007

Bergan L, Gross JA, Nevin B, **Urban N**, **Scholler N**. Development and in vitro validation of anti mesothelin biobodies that prevent CA125/mesothelin-dependant cell attachment. *Cancer Lett*. 2007; 255 (2):263-74.

Goff BA, Mandel LS, **Drescher CW**, **Urban N**, Gough S, Schurman KM, Patras J, Mahoney BS, **Andersen MR**. Development of an ovarian cancer symptom index. *Cancer*. 2007; 109:221-7.

McIntosh MW, Liu Y, **Drescher C**, **Urban N**, Diamandis EP. Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma. *Clin Cancer Res*. 2007;13(15 Pt 1):4422-8.

Scholler N, Garvik B, Hayden-Ledbetter M, Kline T, **Urban N**. Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery. *Cancer Lett*. 2007; 247 (1):130-6.

Simon I, Liu Y, Krall K, **Urban N**, Wolfert R, Kim N, **McIntosh M**. Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer. *Gynecol Oncol*. 2007; 106(1): 112-8.

Thorpe JD, Duan X, Forrest R, **Lowe K**, Brown L, Segal E, **Nelson B**, **Anderson GL**, **McIntosh M**, **Urban N**. Effects of blood collection conditions on ovarian cancer serum markers. PLoS ONE. 2007 Dec;2(12):e1281. PMID: PMC2093996

Urban ND, Longton GM, Crowe AD, Drucker MJ, Lehman CD, Peacock S, **Lowe KA**, Zeliadt SB, Gaul MA. Computer-Assisted Mammography Feedback Program (CAMFP): An electronic tool for continuing medical education. Academic Radiology. 2007 Sep;14(9):1036-42. PMID: PMC2096616

2006

Chiang JW, **Karlan BY**, Cass I, **Baldwin RL**. BRCA1 promoter methylation predicts adverse ovarian cancer prognosis. Gynecol Oncol 2006; 101 (3):403-10.

Goodell V, **Salazar LG**, **Urban N**, **Drescher CW**, Gray H, **Swensen RE**, **McIntosh MW**, **Disis ML**. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J Clin Oncol 2006;24: 762-8.

Hellström I, Raycraft J, Kanan S, Sardesai NY, Verch T, Yang Y, **Hellström KE**. Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev. 2006; 15 (5):1014-20.

Scholler N, Garvik B, Quarles T, Jiang S, **Urban N**. Method for generation of in vivo biotinylated recombinant antibodies by yeast mating. J Immunol Methods. 2006; 317 (1-2):132-43. PMID: PMC1784068

Scholler N, Crawford M, Sato A, **Drescher CW**, O'briant KC, **Kiviat N**, **Anderson GL**, **Urban N**. Bead-Based ELISA for Validation of Ovarian Cancer Early Detection Markers. Clin Cancer Res. 2006 Apr 1;12(7):2117-24.

2005

Andersen MR, Abullarade J, **Urban N**. Assertiveness with physicians is related to women's perceived roles in the medical encounter. Women Health. 2005;42(2):15-33.

Andersen MR, Schroeder T, Gaul M, Moinpour C, **Urban N**. Using a population-based cancer registry for recruitment of newly diagnosed patients with ovarian cancer. Am J Clin Oncol. 2005 Feb;28(1):17-20.

Li AJ, Lerner DL, Gapuzan ME, **Karlan BY**. AIB1 polymorphisms predict aggressive ovarian cancer phenotype. Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2919-22.

Stewart JJ, White JT, Xiaowei Y, **Collins S**, **Drescher CW**, **Urban N**, **Hood L**, **Lin B**. Proteins associated with cisplatin resistance in ovarian cancer cells identified by quantitative proteomics technology and integrated with mRNA expression levels. Mol Cell Proteomics. 2005 Mar 1; 5(3): 433-43.

Tu S-P, Chen H, Chen A, Lim J, May S, **Drescher C**. Clinical trials: Understanding and perceptions of female Chinese-American cancer patients. Cancer. 2005;104: 2999-3005.

2004

McIntosh MW, **Drescher C**, **Karlan B**, **Scholler N**, **Urban N**, **Hellström KE**, **Hellström I**. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol. 2004 Oct;95(1):9-15.

Yang S, Yang Y, Raycraft J, Zhang H, Kanan S, Guo Y, Ronai Z, **Hellström I**, **Hellström, KE**. Melanoma cells transfected to express CD83 induce anti-tumor immunity that can be increased by also engaging CD137. Proc Natl Acad Sci. 2004;101, 4990-5.

2003

Baldwin RL, Tran H, **Karlan BY**. Loss of c-myc repression coincides with ovarian cancer resistance to transforming growth factor beta growth arrest independent of transforming growth factor beta/Smad signaling. Cancer Res. 2003 Mar 15;63(6):1413-9.

Hellström I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, **Schummer M**, **McIntosh M**, **Drescher C**, **Urban N**, **Hellström KE**. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003 Jul 1;63(13):3695-700.

Hellström KE, **Hellström I**. Therapeutic vaccination with tumor cells that engage CD137. J Mol Med. 2003; 81:71-86.

McIntosh MW, Urban N. A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker. *Biostatistics*. 2003; 4:27-40.

Pepe MS, Longton G, Anderson G, Schummer M. Selecting Differentially Expressed Genes from Microarray Experiments. *Biometrics*. 2003; 59:133-42.

Stone B, Schummer M, Paley PJ, Thompson L, Stewart J, Ford M, Crawford M, Urban N, O'Briant K, Nelson BH. Serologic analysis of ovarian tumor antigens reveals a bias toward antigens encoded on 17q. *Int J Cancer*. 2003 Mar 10;104(1):73-84.

2002

McIntosh M, Urban N, Karlan B. Generating Longitudinal Screening Algorithms Using Novel Biomarkers for Disease. *Cancer Epidemiol Biomarkers Prev*. 2002 February 1, 2002;11(2):159-66.

2001

Hellström I, Ledbetter JA, Scholler N, Yang Y, Ye Z, Goodman G, Pullman J, Hayden-Ledbetter M, Hellström KE. CD3-mediated activation of tumor-reactive lymphocytes from patients with advanced cancer. *Proc Natl Acad Sci USA*. 2001;98(12):6783-8.